绝经前淋巴结阳性激素受体阳性早期乳腺癌患者接受5年辅助LHRHa后延长内分泌治疗的队列研究
该队列研究纳入501例≤40岁诊断、淋巴结阳性、激素受体阳性且完成5年辅助LHRHa后仍绝经前的早期乳腺癌患者,比较延长内分泌治疗(eET,n=287)与未延长者的获益。
要点
- 5年LHRHa后延长内分泌治疗与浸润性及远处复发风险降低相关。
- eET组5年IBCFS 85%,非eET组78%,HR 0.63(95%CI 0.44-0.89)。
- 两组骨骨折和主要心血管事件报告率均为1%。
核心结论
- 在完成5年LHRHa治疗的绝经前淋巴结阳性早期乳腺癌患者中,延长内分泌治疗与浸润性和远处乳腺癌复发的临床有意义降低相关。
研究设计与样本
- 对两个前瞻性收集的数据集(Young Women's Breast Cancer Study和IEO Breast Cancer Cohort)进行队列研究分析。
- 纳入2005至2016年间年龄≤40岁诊断、淋巴结阳性、激素受体阳性、完成5年辅助LHRHa后仍绝经前且无复发证据的早期乳腺癌患者,共501例。
- 主要终点为无浸润性乳腺癌生存期(IBCFS),从辅助内分泌治疗开始后第6年(研究基线)计算,并经倾向评分加权分析调整。
主要发现
- 287例接受延长内分泌治疗,中位持续时间3.7年(IQR 2.3-5.0),其中48%为他莫昔芬单药,52%为LHRHa联合他莫昔芬或芳香化酶抑制剂。
- 倾向评分加权后5年无远处复发生存率在eET组为91%,非eET组为83%(Cause-specific HR 0.49,95%CI 0.31-0.79)。
- 两组骨骨折和主要心血管事件报告率均为1%。
临床怎么用
- 对于完成5年辅助LHRHa治疗且仍处于绝经前、淋巴结阳性、激素受体阳性的早期乳腺癌患者,可考虑延长内分泌治疗以降低复发风险。
- 延长内分泌治疗决策需结合个体复发风险及耐受性,关注骨健康与心血管事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the clinical benefit of extended endocrine therapy (eET) after 5 years of adjuvant treatment with luteinizing hormone-releasing hormone agonists (LHRHa) in premenopausal women with node-positive, hormone receptor-positive early breast cancer (eBC). METHODS: We conducted a cohort study analysis on two prospectively collected data sets (the Young Women's Breast Cancer Study and IEO Breast Cancer Cohort). Eligible patients were diagnosed with eBC at age ≤40 years (between 2005 and 2016), had node-positive, hormone receptor-positive disease, and remained premenopausal after 5 years of adjuvant LHRHa with no evidence of recurrence. The primary end point was invasive breast cancer-free survival (IBCFS), calculated from the sixth year after the initiation of adjuvant endocrine therapy (ET; study baseline), and adjusted through the propensity score (PS) weighting analysis. RESULTS: A total of 501 patients were included in the analysis: 287 received eET for a median duration of 3.7 years (IQR, 2.3-5.0), including 48% tamoxifen monotherapy and 52% LHRHa plus tamoxifen or aromatase inhibitor. After a median follow-up of 7.3 years from the study baseline, the PS weighted IBCFS rates at 5 years were 85% in the eET group and 78% in the non-eET group (hazard ratio [HR], 0.63 [95% CI, 0.44 to 0.89]; P = .0135). The PS weighted distant recurrence-free survival rates at 5 years were 91% and 83% in the eET and non-eET group, respectively (cause-specific HR, 0.49 [95% CI, 0.31 to 0.79]). In both groups, bone fractures and major cardiovascular events were reported in 1% of patients. CONCLUSION: In this cohort study analysis, extending ET in premenopausal patients with node-positive eBC after 5 years of LHRHa treatment was associated with a clinically meaningful reduction in both invasive and distant breast cancer recurrences.
引用
- Valenza C, Zheng Y, Milano M, et al. Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study. J Clin Oncol. 2026. PMID: 41538747. doi:10.1200/JCO-25-01660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。